Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas.
Michael J FuscoYolanda PiñaRobert J MacaulaySolmaz SahebjamPeter A ForsythEdwin PegueroChristine M WalkoPublished in: Cancer control : journal of the Moffitt Cancer Center (2022)
V600 E mutations, especially those that are resistant to standard therapy. Our cases, along with other early reports utilizing dabrafenib/trametinib, highlight the importance of somatic next-generation sequencing, particularly in younger patients. Interim results from clinical trials utilizing dabrafenib/trametinib have been promising thus far, and our case series suggests that durable clinical benefit is possible, even in the setting of glioblastoma, WHO grade IV.
Keyphrases
- free survival
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- copy number
- peritoneal dialysis
- high grade
- metastatic colorectal cancer
- prognostic factors
- randomized controlled trial
- emergency department
- stem cells
- gene expression
- signaling pathway
- mesenchymal stem cells
- dna methylation
- open label
- electronic health record
- phase iii
- circulating tumor
- chemotherapy induced